Animal models of Parkinson's disease and their applications

被引:6
|
作者
Park, Hyun Jin [1 ]
Zhao, Ting Ting [1 ]
Lee, Myung Koo [1 ]
机构
[1] Chungbuk Natl Univ, Dept Pharm, Res Ctr Bioresource & Hlth, Coll Pharm, 1 Chungdae Ro, Cheongju 28644, South Korea
基金
新加坡国家研究基金会;
关键词
Parkinson's disease; neurotoxin animal models; genetic animal models; adjuvant therapeutics;
D O I
10.2147/JPRLS.S85419
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disorder that occurs mainly due to the degeneration of dopaminergic neuronal cells in the substantia nigra. L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective known therapy for PD. However, chronic L-DOPA administration results in a loss of drug efficacy and irreversible adverse effects, including L-DOPA-induced dyskinesia, affective disorders, and cognitive function disorders. To study the motor and non-motor symptomatic dysfunctions in PD, neurotoxin and genetic animal models of PD have been widely applied. However, these animal models do not exhibit all of the pathophysiological symptoms of PD. Regardless, neurotoxin rat and mouse models of PD have been commonly used in the development of bioactive components from natural herbal medicines. Here, the main animal models of PD and their applications have been introduced in order to aid the development of therapeutic and adjuvant agents.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Parkinson's disease: animal models and dopaminergic cell vulnerability
    Blesa, Javier
    Przedborski, Serge
    FRONTIERS IN NEUROANATOMY, 2014, 8
  • [42] Neuroprotection by estrogen in animal models of ischemia and Parkinson's disease
    Merchenthaler, I
    Shughrue, PJ
    DRUG DEVELOPMENT RESEARCH, 2005, 66 (02) : 172 - 181
  • [43] Cardiovascular Autonomic Dysfunction in Animal Models of Parkinson's Disease
    Fleming, Sheila M.
    JOURNAL OF PARKINSONS DISEASE, 2011, 1 (04) : 321 - 327
  • [44] Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease
    Bridget Martinez
    Philip V.Peplow
    Neural Regeneration Research, 2018, 13 (09) : 1493 - 1506
  • [45] Estrogen and SERM neuroprotection in animal models of Parkinson's disease
    Morissette, Marc
    Al Sweidi, Sara
    Callier, Sophie
    Di Paolo, Therese
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 290 (1-2) : 60 - 69
  • [46] Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease
    Rosalba Siracusa
    Irene Paterniti
    Marika Cordaro
    Rosalia Crupi
    Giuseppe Bruschetta
    Michela Campolo
    Salvatore Cuzzocrea
    Emanuela Esposito
    Molecular Neurobiology, 2018, 55 : 2403 - 2419
  • [47] Evaluation of animal models of Parkinson's disease for neuroprotective strategies
    Emborg, ME
    JOURNAL OF NEUROSCIENCE METHODS, 2004, 139 (02) : 121 - 143
  • [48] Exploring the Peripheral Initiation of Parkinson's Disease in Animal Models
    Sorrentino, Zachary A.
    Giasson, Benoit I.
    NEURON, 2019, 103 (04) : 547 - 549
  • [49] Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective
    Banerjee, Rajashree
    Rai, Arushi
    Iyer, Shreyas M.
    Narwal, Sonia
    Tare, Meghana
    ANIMAL MODELS AND EXPERIMENTAL MEDICINE, 2022, 5 (01) : 27 - 37
  • [50] Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease
    Diguet, E
    Fernagut, PO
    Wei, X
    Du, Y
    Bezard, E
    Tison, F
    MOVEMENT DISORDERS, 2004, 19 : S388 - S388